1. RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION
- Author
-
Nagahisa Yoshimura, Ayako Takahashi, Yoshimasa Kuroda, Manabu Miyata, Hiroshi Tamura, Sotaro Ooto, Akitaka Tsujikawa, Masayuki Hata, Naoko Ueda-Arakawa, Akio Oishi, and Kenji Yamashiro
- Subjects
0301 basic medicine ,Retinal degeneration ,Male ,Pathology ,Time Factors ,medicine.medical_treatment ,Visual Acuity ,Angiogenesis Inhibitors ,Retinal Pigment Epithelium ,chemistry.chemical_compound ,0302 clinical medicine ,Fluorescein Angiography ,Aged, 80 and over ,medicine.diagnostic_test ,Retinal Degeneration ,General Medicine ,Anatomy ,Fluorescein angiography ,medicine.anatomical_structure ,Treatment Outcome ,Intravitreal Injections ,Retinal pigment epithelial atrophy ,Female ,Tomography, Optical Coherence ,medicine.drug ,medicine.medical_specialty ,Fundus Oculi ,Recombinant Fusion Proteins ,03 medical and health sciences ,Atrophy ,Ranibizumab ,medicine ,Humans ,Retrospective Studies ,Retinal pigment epithelium ,Dose-Response Relationship, Drug ,business.industry ,Growth factor ,Retinal ,medicine.disease ,Ophthalmology ,030104 developmental biology ,Receptors, Vascular Endothelial Growth Factor ,chemistry ,030221 ophthalmology & optometry ,sense organs ,business ,Follow-Up Studies - Abstract
To investigate the incidence rate and risk factors for development of retinal pigment epithelial (RPE) atrophy during anti-vascular endothelial growth factor (anti-VEGF) treatment for retinal angiomatous proliferation.This study included 46 eyes with treatment-naive retinal angiomatous proliferation. All patients were treated with ranibizumab or aflibercept injections. Color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence were evaluated for RPE atrophy diagnosis. Baseline characteristics and gene polymorphisms of ARMS2 A69S, and CFH I62V were analyzed for association with development and progression of RPE atrophy.Among 21 eyes treated with ranibizumab without preexisting RPE atrophy at baseline, 5 eyes (23.8%) developed RPE atrophy at 12 months. Among 20 eyes treated with aflibercept without preexisting RPE atrophy at baseline, 10 eyes (50.0%) developed RPE atrophy at 12 months. Refractile drusen at baseline was associated with RPE atrophy development at 12 months (P = 0.014), and the progression rate of RPE atrophy area was negatively correlated with subfoveal choroidal thickness at baseline (R = -0.595, P = 0.019). Gene polymorphisms were not associated with RPE atrophy.Retinal pigment epithelial atrophy developed in 36.6% during 12 months after anti-VEGF treatment for retinal angiomatous proliferation. The presence of refractile drusen at baseline was identified as a novel significant risk factor for RPE atrophy development.
- Published
- 2017